D-3307 Dasatinib, Free Base, >99%

Synonyms : [BMS-354825]

Related Terms : [Sprycel]

  • Size
  • US $
  • £
  • ¥
  • 500 mg
  • 42
  • 38
  • 34
  • 4,600
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 57
  • 52
  • 46
  • 6,200
  • Add to Cart Qty:
  • In stock
  • 2 g
  • 98
  • 90
  • 79
  • 10,600
  • Add to Cart Qty:
  • In stock
  • 5 g
  • 155
  • 143
  • 126
  • 16,800
  • Add to Cart Qty:
  • In stock
  • 10 g
  • 230
  • 212
  • 187
  • 24,900
  • Add to Cart Qty:
  • In stock
  • 25 g
  • 475
  • 439
  • 387
  • 51,500
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 33 Other Countries
  • M.W. 488.01
  • C22H26ClN7O2S
  • [302962-49-8]
  • M.I. 14: 2829

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 200 mg/mL; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • More than 830 labs worldwide have purchased Dasatinib from LC Labs (either directly from us or from our many distributors, many of whom resell under their own labels).
  • Small molecule inhibitor of both the SRC and BCR/ABL tyrosine kinases, with IC50's for the isolated kinases of 0.55 and 3.0 nM, respectively. Lombardo, L.J., et al. "Discovery of N-(2-chloro-6-methylphneyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in pre-clinical assays." J. Med. Chem. 47: 6658-6661 (2004).
  • Dasatinib also inhibits Lyn (IC50 = 8.5 nM) and Src (IC50 = 3.0 nM) kinase activities in vitro using 0.1 mg/mL poly (Glu4-Tyr) as the substrate. Nam, S., et al. "Action of the Src Family Kinase Inhibitor, Dasatinib (BMS-354825), on Human Prostate Cancer Cells." Cancer Res. 65: 9185-9189 (2005).
  • Dasatinib has greater potency than imatinib mesylate and has activity against the majority of kinase mutations in imatinib-resistant chronic myeloid leukemia. Copland, M., et al. "Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction." Blood 107: 4532-4539 (2006).
  • Dasatinib and nilotinib are respectively 325-fold (IC50: 0.6 versus 280 nM) and 20-fold (IC50: 15 versus 280 nM) more potent than imatinib against cells expressing wild-type Bcr-Abl. Similar improvements are also seen in all imatinib-resistant mutants tested, with the exception of T315I. Both inhibitors have activity against imatinib-refractory chronic myelogenous leukemia. O'Hare, T., et al. "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants." Cancer Res. 65: 4500-4505 (2005).
  • The CAS number for the monohydrate form of dasatinib is [863127-77-9].
  • Dasatinib is the active ingredient in the drug product sold under the trade name Sprycel®.  This drug has been approved in at least one country for use in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myelogenous leukemia.  NOTE: THE DASATINIB SOLD BY LC LABORATORIES FOR RESEARCH IS NOT SPRYCEL®, AND IS NOT FOR HUMAN USE.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.